NR4A1 and hepatocellular carcinoma: On the contrary, our observations demonstrate that NDRG1 is an oncogenic activator in HCC, possibly through its competitive binding with GSK-3β and Nur77 which reduces β-catenin degradation and enhances β-catenin transcriptional activation of its downstream oncogenes.